Genetics and Screening Drive Lung Cancer Fight

Lung cancer screening with low‑dose CT (LDCT) is gaining attention as a tool that could shift survival odds for many Americans, yet uptake remains low despite clear evidence of benefit.

How LDCT Works and Why Early Detection Matters

LDCT uses a reduced radiation dose compared with conventional CT scans but still yields detailed images of lung tissue. “It’s just done at a lower radiation dose, but at a high enough level that we can find abnormalities suspicious for lung cancer,” explained Dr. Anil Vachani, pulmonologist and director of lung cancer screening at NYU Langone Health.

When cancers are caught at stage 1A, the chance of cure climbs to roughly 90% through surgery or stereotactic body radiation therapy. Dr. Andrea McKee of the American Lung Association noted that without screening, about 70% of diagnoses occur at a late stage, when treatment options are limited.

Annual LDCT screening can lower lung‑cancer mortality among high‑risk individuals. The test carries a false‑positive rate of about 10%. Follow‑up procedures such as bronchoscopy or needle aspiration are sometimes required, adding modest risk of infection or lung injury.

Who Qualifies and Why Many Miss the Mark

The U.S. Preventive Services Task Force recommends yearly LDCT for people aged 50 to 80 who have smoked at least a 20 pack‑year history and who currently smoke or quit within the past 15 years. This definition captures many at highest risk but excludes roughly half of current lung‑cancer patients, who either have lighter smoking histories or none at all.

Genetic predisposition and family history also influence risk, yet they are not part of current screening criteria. Environmental factors such as radon exposure, air pollution, and workplace chemicals further complicate risk assessment. As a result, many individuals who could benefit from early detection remain unaware of their eligibility.

Barriers to screening include lack of awareness, cost concerns, and logistical challenges.

Patients who are eligible should discuss LDCT with their providers, especially if they have a family history of lung cancer or known environmental exposures. The test’s radiation dose is low enough that, for high‑risk individuals, it should not be a deterrent.

Most positive findings are benign, and the screening program’s net benefit remains positive for the target population.

Screening rates have risen from under 4% of eligible adults in 2015 to about 18% in 2022, reflecting growing awareness and better program implementation.